1 . Erdem H, Gündogdu C, Şipal S. "Correlation of E-cadherin, VEGF, COX-2 expression to prognostic parameters in papillary thyroid carcinoma" . Experimental and molecular pathology. 2011; 90(3):312-7.

2 . Krawczyk-Rusiecka K, Lewiński A. "Cyclooxygenase-2 expression and its association with thyroid lesions" . Archives of medical science: AMS. 2010; 6(5):653.

3 . Tsujii M, DuBois RN. "Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2" . Cell. 1995; 83(3):493-501.

4 . Siironen P, Ristimaki A, Narko K, Nordling S, Louhimo J, Andersson S, et al.. "VEGF-C and COX-2 expression in papillary thyroid cancer" . Endocrine-Related Cancer. 2006; 13(2):465-73.

5 . Al-Maghrabi J, Emam E, Gomaa W, Saggaf M, Buhmeida A, Al-Qahtani M, et al.. "c-MET immunostaining in colorectal carcinoma is associated with local disease recurrence" . BMC Cancer. 2015; 15:676.

6 . Al-Maghrabi B, Gomaa W, Abdelwahed M, Al-Maghrabi J. "Increased COX-2 Immunostaining in Urothelial Carcinoma of the Urinary Bladder Is Associated with Invasiveness and Poor Prognosis" . Anal Cell Pathol (Amst). 2019; 2019:5026939.

7 . Margulis V, Shariat SF, Ashfaq R, Thompson M, Sagalowsky AI, Hsieh JT, et al.. "Expression of cyclooxygenase-2 in normal urothelium, and superficial and advanced transitional cell carcinoma of bladder" . J Urol. 2007; 177(3):1163-8.

8 . Ke HL, Tu HP, Lin HH, Chai CY, Chang LL, Li WM, et al.. "Cyclooxygenase-2 (COX-2) up-regulation is a prognostic marker for poor clinical outcome of upper tract urothelial cancer" . Anticancer Res. 2012; 32(9):4111-6.

9 . Denkert C, Kobel M, Berger S, Siegert A, Leclere A, Trefzer U, et al.. "Expression of cyclooxygenase 2 in human malignant melanoma" . Cancer Res. 2001; 61(1):303-8.

10 . Yoshimura R, Sano H, Masuda C, Kawamura M, Tsubouchi Y, Chargui J, et al.. "Expression of cyclooxygenase-2 in prostate carcinoma" . Cancer. 2000; 89(3):589-96.

11 . Mazhar D, Gillmore R, Waxman J. "COX and cancer" . QJM. 2005; 98(10):711-8.

12 . Prescott SM. "Is cyclooxygenase-2 the alpha and the omega in cancer?" The Journal of clinical investigation. 2000; 105(11):1511-3.

13 . Larson SD, Jackson LN, Riall TS, Uchida T, Thomas RP, Qiu S, et al.. "Increased incidence of well-differentiated thyroid cancer associated with Hashimoto thyroiditis and the role of the PI3k/Akt pathway" . Journal of the American College of Surgeons. 2007; 204(5):764-73.

14 . Cornetta AJ, Russell JP, Cunnane M, Keane WM, Rothstein JL. "Cyclooxygenase ?2 expression in human thyroid carcinoma and Hashimoto's thyroiditis" . The Laryngoscope. 2002; 112(2):238-42.

15 . García-González M, Abdulkader I, Boquete AV, Neo XML, Forteza J, Cameselle-Teijeiro J. "Cyclooxygenase-2 in normal, hyperplastic and neoplastic follicular cells of the human thyroid gland" . Virchows Archiv. 2005; 447(1):12-7.

16 . Ito Y, Yoshida H, Nakano K, Takamura Y, Miya A, Kobayashi K, et al.. "Cyclooxygenase ?2 expression in thyroid neoplasms" . Histopathology. 2003; 42(5):492-7.

17 . Specht MC, Tucker ON, Hocever M, Gonzalez D, Teng L, Fahey TJ. "Cyclooxygenase-2 expression in thyroid nodules" . The Journal of Clinical Endocrinology & Metabolism. 2002; 87(1):358-63.

18 . Kim SJ, Lee JH, Yoon JS, Mok JO, Kim YJ, Park HK, et al.. "Immunohistochemical expression of COX-2 in thyroid nodules" . The Korean journal of internal medicine. 2003; 18(4):225.

19 . Ji B, Liu Y, Zhang P, Wang Y, Wang G. "COX-2 expression and tumor angiogenesis in thyroid carcinoma patients among northeast Chinese population-result of a single-center study" . Int J Med Sci. 2012; 9(3):237-42.

20 . Ruco L, Scarpino S. "The Pathogenetic Role of the HGF/c-Met System in Papillary Carcinoma of the Thyroid" . Biomedicines. 2014; 2(4):263-74.

21 . Lee HM, Baek SK, Kwon SY, Jung KY, Chae SW, Hwang SJ, et al.. "Cyclooxygenase 1 and 2 expressions in the human thyroid gland" . Eur Arch Otorhinolaryngol. 2006; 263(3):199-204.

22 . Fu X, Zhang H, Chen Z, Yang Z, Shi D, Liu T, et al.. "TFAP2B overexpression contributes to tumor growth and progression of thyroid cancer through the COX-2 signalling pathway" . Cell Death Dis. 2019; 10(6):397.

23 . Kim KH, Kim SH, Kim SH, Back JH, Park MJ, Kim JM. "Cyclooxygenase-2 and inducible nitric oxide synthase expression in thyroid neoplasms and their clinicopathological correlation" . J Korean Med Sci. 2006; 21(6):1064-9.

24 . Kajita S, Ruebel KH, Casey MB, Nakamura N, Lloyd RV. "Role of COX-2, thromboxane A 2 synthase, and prostaglandin I 2 synthase in papillary thyroid carcinoma growth" . Modern Pathology. 2005; 18(2):221.

25 . Giaginis C, Alexandrou P, Delladetsima I, Karavokyros I, Danas E, Giagini A, et al.. "Clinical Significance of Hu-Antigen Receptor (HuR) and Cyclooxygenase-2 (COX-2) Expression in Human Malignant and Benign Thyroid Lesions" . Pathol Oncol Res. 2016; 22(1):189-96.

26 . Siironen P, Ristimaki A, Nordling S, Louhimo J, Haapiainen R, Haglund C. "Expression of COX-2 is increased with age in papillary thyroid cancer" . Histopathology. 2004; 44(5):490-7.

27 . Parvathareddy SK, Siraj AK, Annaiyappanaidu P, Al-Sobhi SS, Al-Dayel F, Al-Kuraya KS. "Prognostic Significance of COX-2 Overexpression in BRAF-Mutated Middle Eastern Papillary Thyroid Carcinoma" . Int J Mol Sci. 2020; 21(24).

28 . Ji B, Liu Y, Zhang P, Wang Y, Wang G. "COX-2 expression and tumor angiogenesis in thyroid carcinoma patients among northeast Chinese population-result of a single-center study" . International journal of medical sciences. 2012; 9(3):237.

29 . Sheils O. "Molecular classification and biomarker discovery in papillary thyroid carcinoma" . Expert Rev Mol Diagn. 2005; 5(6):927-46.